Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
BlueRock Therapeutics Advances Bemdaneprocel to Phase III Trial for Parkinson’s
Details : BRT-DA01 (bemdaneprocel) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 13, 2025
BlueRock’s Bemdaneprocel Shows Positive Data at 24 Months for Parkinson’s Disease
Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 27, 2024
BlueRock's Phase I Trial for Parkinson’s Shows Positive Trends at 18 Months
Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 03, 2024
BlueRock Therapeutics Gets FDA RMAT Designation for Parkinson’s Disease Cell Therapy
Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 31, 2024
Details : BRT-DA01 (bemdaneprocel) is an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into the brain of a person with Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 10, 2023
Details : The primary objective of the Ph1 trial is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant. The secondary objectives, are to assess the evidence of transplanted cell survival and motor effects at one and two-...
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 01, 2022
Details : The primary objective of the Ph1 trial is to assess the safety and tolerability of BRT-DA01 transplantation at one-year post-transplant. The secondary objectives are to assess the evidence of transplanted cell survival and motor effects at one- and two-y...
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 31, 2022
Details : The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and preliminary efficacy of DA01. DA01 is being clinically evaluated in a subset of patients with advanced Parkinson’s disease, where regular medications are no longer fully ...
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 18, 2022
Details : Based on safety, tolerability, and the immune response generated by 144 children in the Phase I study of the two-dose shot, Pfizer will test a dose of BNT162b2 10mg in children between 5-11 years, and 3mg for the age group of 6-5 years old.
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 06, 2021
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01
Details : The primary objective of the Ph1 study is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 19, 2021
Reset All
